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Podocin (NPHS2) expression in podocytes is associated with
variable degrees of proteinuria and progression to renal
failure in different glomerular diseases that suggests different
expression profiles in NPHS2 promoter. Three functional
polymorphisms in NPHS2 promoter (51T, 116T, and
535 insCTTTTTT3) were found determining strong
downregulation (73, 59, and 82%, respectively) of the
reporter gene expression when transfected in podocytes.
Electrophoretic mobility shift assay experiments showed that
all wild-type variants (51G, 116C, and 535 insCTTTTTT2)
formed specific DNA–protein complexes with podocyte
nuclear extracts that were abolished by the presence of the
rare forms (51T, 116T, and 535 insCTTTTTT3). In the case
of 51G, upstream stimulatory factor-1 (USF1) was identified
as the specific trans element in accord to binding inhibition
experiments and USF1 RNAi silencing. Haplotype analysis of
204 normal controls and 545 patients with renal diseases
(308 immunoglobulin (Ig)A nephropathy and 237 focal
segmental glomerulosclerosis) evidenced that 116/51
and 535/P2OL formed two blocks in strong linkage
disequilibrium in both normal and pathological cohorts.
The high NPHS2 promoter profile 116C/51G haplotype
was more frequent in patients with IgA nephropathy
(P-value¼ 0.005) and was associated with a better clinical
outcome in terms of proteinuria and creatinine levels. Overall
our study describes functional variants of NPHS2 promoter
and characterizes trans-acting elements that modulate
podocin expression in the kidney. High producer NPHS2
promoter haplotypes seem protective in patients with
chronic glomerular diseases.
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Glomerular diseases, such as focal segmental glomerulo-
sclerosis (FSGS) and IgA nephropathy (IgA), affect a bulk of
patients evolving to end-stage renal failure (ESRF). Protei-
nuria is the common clinical feature and represents a key
motif for disease progression.1,2 Definition of the mechan-
isms involved in proteinuria, their prediction and prevention
remain, together with the genetic contribution, a central
theme in the current research.3,4 Glomerular slit-diaphragm
and the specialized proteins nephrin, podocin, and CD2AP,
which form the ultrafiltration unit, are potential culprits of
proteinuric insults, and podocin has a central role in it.5–8
Associations of podocin defects with proteinuria and ESRF
are increasingly reported in animal models and in humans.9
Accordingly, targeted knockout of NPHS2 (the gene coding
for podocin) leads to proteinuria and renal failure in mice10
and inherited mutations of NPHS2 sequence are the major
cause of nephrotic syndrome in children who invariably
evolve to renal failure.11–13
Like several other glomerular proteins, podocin expression
in proteinuric renal diseases appears to be a dynamic process
that results in marked decrease of protein expression.14,15 It is
still unknown whether podocin mRNA is up or down-
regulated and results of the literature lead to opposite
conclusions. Koop et al.14 reported a significant increase in
podocin mRNA in minimal change nephropathy and FSGS,
proposing a compensatory reaction of the damaged podo-
cytes. Results by Schmid et al.16 pointed to a differentiation
between FSGS and minimal change disease, the former being
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characterized by downregulation of podocin mRNA glomer-
ular expression. In spite of these inconsistencies, the real data
are that podocin expression, at the protein level, is markedly
downregulated and abnormally distributed in both
conditions. According to structural models, this should
interfere with slit-diaphragm architecture and function7,17
and eventually influence proteinuria. It seems likely
that restoration of normal podocin composition should
modify this aspect and, depending on reparative capacities of
the renal barrier, also play a role in the disease evolution.
Podocin promoter has been located in the 2.5 kb of the
50 terminus of NPHS2 gene (GenBank accession number
AF487463) by demonstrating direct podocyte-specific
expression in transgenic mice.18,19 We recently demonstrated
that the NPHS2 promoter fragment from –628 to ATG is
able to specifically direct podocin expression in different cell
lines including human glomerular epithelial cells.20 We
carried out a sequencing study of the promoter region from
–628 to ATG in a large cohort of patients affected by
glomerular diseases, looking for variants that could affect
podocin expression.
RESULTS
Polymorphic variants in NPHS2 promoter
We evaluated 749 DNA from patients with primary nephrotic
syndrome (237), IgA nephropathy (308) and controls (204).
Criteria for enrolment are described below and clinical
characteristics of the study group are shown in Table 1. All
patients were of Italian origin; IgA patients represent the
Italian branch afferent to the Consortium on IgA nephro-
pathy.21 According to regional enrolment, normal control
DNA were obtained from Italian people enrolled in the same
regions as patients. Sequencing of all DNA demonstrated 10
variants of NPHS2 with a minor allele frequency higher than
1% in at least one group: seven were located in exons or
flanking coding regions, three were in the promoter region up
to –628 from ATG (Table 2). Rare promoter variants with an
allele frequency lower than 1% had been described separately
and were not considered in the present paper.20 Variants at 50
untranslated region underwent functional studies in order to
demonstrate implication in podocin expression.
The haplotype frequencies were estimated from the
sample of unrelated cases and controls by use of the
Table 1 | General and clinical features of normal controls and two different cohorts of patients with renal disease (nephrotic
syndrome, IgA nephropathy) both characterized by glomerular damage and proteinuria
Number Controls Nephrotic syndrome IgA
(N=204) (N=237) (N=308)
Gender (#) 120 (58%) 139 (59%) 241 (78%)
Mean age at onset (years) 38 (18–46) 17 (1–62) 21 (4–76)
Histology
IgA grades 1–5 308 (100%)
G1–2 (32%)
G3–4 (54%)
G5 (14%)
Nephrotic syndrome
MCN 25 (21; 1–59)
IgM 54 (9; 1–50)
FSGS 138 (22; 1–62)
Clinical presentation
Nephrotic syndrome 237 (100%) Microematuria 241 (100%)
Macroematuria 196 (81%)
Proteinuria o1 g 122 (52%)
proteinuria 41 g 119 (49%)
Therapy
Steroid 232 (98%)
Levam 17 (7%)
Clo/Cyclo 83 (35%)
CsA 103 (43%)
Response to drugs
Responders 16 (16; 2–21)
Frequent relapse 22 (18; 1–61)
Steroid dependent 43 (10; 2–51)
Steroid resistant 150 (19; 1–39)
ESRF 79 (33%) 53 (17%)
Csa, cyclosporin A; Clo/cyclo, chlorambucil/cyclophosphamide; ESRF, end-stage renal failure; FSGS, focal segmental glomerulosclerosis; IgM, IgM deposit; levam, levamisole;
MCN, minimal change nephropathy. Age at onset for all categories, histology and response to drugs for the nephrotic syndrome group are expressed as mean and range.
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maximum-likehood estimates. All 46 possible pairwise D0
values among cases and controls were calculated and the
significance level was evaluated by the w2 test and permuta-
tion tests as implemented Haploview 3.2,22 PHASE 2.023 and
UNPHASED 2.40424 programs. An unique recurrent marker
pair was in complete linkage disequilibrium (LD) (D0 ¼ 1.00)
in controls, nephrotic syndrome, and IgA patients, that
included the two variants at 51 and 116 from 50
untranslated region that strictly correlated with distance
(Figure 1a and b). In patients with nephrotic syndrome was
striking the observation of the aminoacidic variant P20L only
in individuals carrying the 535CTTTTTT3 allele. Parent–-
child transmission (Figure 2) showed that these two
variants are in fact in phase. Haplotype reconstruction
from population genotype data confirmed this finding
showing a block of linkage disequilibrium including
535CTTTTTT3 /P20L/G34G. A second block included the
two synonymous nucleotide variants L236L and A318A at
exons 8 (Figure 1a).
The frequency of every single haplotype in cases and in
controls are reported in Table 3.
Functional implication of NPHS2 promoter variants
Functional implications of each sequence variants in NPHS2
promoter were studied following consolidated recipes based
on subcloning in pGL3 reporter vector and transient
transfection experiments in glomerular epithelial cells
(Figure 3) and COS7 cells. A significant reduction of
luciferase expression by podocytes compared to the wild-
type sequence was determined in all the three variants
51G4T, 116C4T, and 535CTTTTTT3, producing
73, 59, and 82% reduction, respectively (Po0.001)
(Figure 3) and were confirmed in COS7 cells (not shown).
Binding of transcriptional factors, or protein complexes, and
their characterization was investigated in the regions
surrounding these polymorphisms.
51G4T. Electrophoretic mobility shift assay (EMSA)
experiments using podocyte nuclear extracts and oligo-
nucleotide 51G demonstrated the formation of a slowly
migrating complex that was not formed in case of the 51T
(Figure 4a, tracks 1, 2). Competition studies with unlabelled
51G at three different concentrations of 100–200–400 M
Table 2 | Genetic variants with a minor allele frequency 41%, identified in cases and controls
Name Location
Minor allele frequencies
Nucleotide substitution db SNP identifier
Controls Nephrotic syndrome IgA nephropathy
535 Promoter 0.012 0.015 0.016 535CTTTTTT24CTTTTTT3
116 Promoter 0.343 0.318 0.283 116C4T rs12406197
51 Promoter 0.250 0.244 0.201 51G4T
P20L Exon 1 0.000 0.013 0.003 c.59C4T
G34G Exon 1 0.012 0.019 0.008 c.102G4A rs3818588
S96S Exon 2 0.041 0.043 0.077 c.289C4T rs3738423
R229Q Exon 5 0.017 0.025 0.007 c.686G4A
IVS7+7 Intron 7 0.076 0.066 0.063 IVS7+7A4G
A318A Exon 8 0.359 0.371 0.357 c.954T4C rs1410592
L346L Exon 8 0.038 0.049 0.061 c.1038A4G rs3818587
SNP, single nucleotide polymorphism.
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Figure 1 | Haploview showing the haplotype association of
different SNPs in nephrotic and IgA patients. Pairwise LD plots
between NPHS2 gene polymorphisms calculated on the cohort of
(a) 237 nephrotic syndrome individuals and (b) on 308 IgA patients.
Dark gray boxes correspond to pairs of polymorphisms with strong
evidence of LD, light gray to uninformative pairs, white to
pairs of polymorphisms with strong evidence of recombination.
The numbers inside the boxes represent the D0 values.
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excess and lack of competition of  51T confirmed specificity
of the complex (Figure 4a, tracks 5, 6, 7, and 8). Consensus
analysis for homology of 51 variant region with regulatory
sequences revealed homology for two transcriptional factors,
that is, USF1 and hypoxia-inducible factor 1 A. Preincuba-
tion with anti-USF1 (but not antibodies directed to another
unrelated transcriptional factor such as cfos) antibodies
abolished the formation of the retarded complex (Figure 4a,
tracks 3 and 4), indicating that this is the transcriptional
factor that binds this cis element. Further experiments were
performed to confirm this conclusion. In a first set,
degenerate (51G: 50-TGCGCTCCGGTGCCCCTAGC-30)
(the bold indicates the base that makes the difference
between degenerate and typical USF E-box) and typical
sequences for USF E-box (50-TGCGCTCACGTGCCCC
TAGC-30) were run in parallel and showed comigration at
the same molecular weight (Figure 4b, tracks 1 and 3)
whereas hypoxia-inducible factor 1 A did not form oligo-
protein complexes (not shown). In the case of typical E-box,
it was evident the formation of a marked protein–DNA
adduct (Figure 4b, track 3) that overwhelmed by several
factors the DNA–protein complex formed by degenerate
sequences (compare tracks 1 and 3 in Figure 4b). The
presence of anti-USF1 antibodies abolished the formation of
the complex (Figure 4b, track 4) and produced a super-shift
that is represented by a band with higher molecular weight
and an intensity that is less than 10% of the original adduct.
This suggests that only a minor part of the complex forms
polymers and justify the observed lack of super-shift
formation with degenerate sequences (Figure 4b, track 5).
Our data support the concept that USF1 forms an adduct
with a degenerate consensus sequence in NPHS2 promoter
and regulates the expression of podocin. To confirm this
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Figure 2 | Haplotypes reconstruction in two small families (out of
six) in which the index case presented the P20L variant. Squares
represent males, circles represent females. Filled symbols, affected
individuals; open symbols, unaffected individuals.
Table 3 | Haplotypes frequencies observed in controls and cases that include nephrotic syndrome (NS) and IgA
nephropathy (IgA)
Haplotype Controls (%) NS (%) P-value Corr. P-value IgA (%) P-value Corr. P-value
116/51
C/G 41 44 NS NS 52 0.0006 0.005
C/T 25 24 NS NS 20 NS NS
T/G 34 32 NS vs controls NS 28 0.041 vs controls NS
535/P20L/G34G
535CTTTTTT3/T/A 0 1.3 0.023 0.035 0.3 NS NS
535CTTTTTT3/C/A 1 0.2 NS NS 0.3 NS NS
535CTTTTTT2/C/A 0.2 0.4 NS NS 0.2 NS NS
535CTTTTTT3/C/G 0.2 0 NS vs controls NS 1.2 NS vs controls NS
A318A/L346L
T/A 64 63 NS NS 64 NS NS
C/A 32 32 NS NS 30 NS NS
C/G 4 5 NS vs controls NS 6 NS vs controls NS
NS, not significant.
P-values for the case–control comparisons are reported as nominal P-values and corrected for multiple comparisons by permutation test (10 000 replicates).
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Figure 3 | Luciferase expression in podocytes transfected with
constructs of the three single nucleotide polymorphisms variants
535CTTTTTT3, 116C4T, and 51G4T compared to the
wild-type sequences (535CTTTTTT2, 51G, 116C). In all cases,
the reductions in the expression levels (73, 59, and 82%,
respectively) were highly significant (Po0.001) owing to
the reproducibility of expression experiments.
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point, podocytes were silenced for USF1 RNA expression and
transfected with wild-type constructs containing the 51G
sequence. As shown in Figure 4a and b, silencing produced a
50% expression of USF1 at Western blot (Figure 5a) and
induced in parallel 30% reduction of luciferase expression
(Figure 5b), a finding that conclusively supports USF1
functional implication.
116C4T. Formation of DNA–protein complex was
observed by incubation with nuclear extracts of wild-type
116C (50-CAGCCCCCACCCGACGGTCTTTAGGGTCCC-
30) that is associated with high expression profile in the
luciferase assay (Figure 6, track 2), whereas the presence of a
T in the same position abolished the formation of the
retarded complex (Figure 6, track 1). Also in this case,
competition with unlabelled oligonucleotide 100, 200, and
400 M excess abolished the adduct formation, indicating
specificity of the binding (Figure 6, tracks 3, 4 and 5).
Searching databases for transcription factor binding sites
failed to identify transcription factors docking to 116C.
535CTTTTTT3. Incubation of the wild-type 535CTT
TTTT2 with nuclear extracts did not induce the formation of
any adduct. The presence of a 535CTTTTTT3 at this site
produced the formation of a marked protein–DNA slow
migrating complex that is evident in Figure 7, track 2. As the
presence of the more frequent variant is associated with a
high luciferase profile whereas the rare variant observed in
association with P20L in FSGS patients abolished luciferase
expression by 80%, we concluded that the transcriptional
factor that binds this site plays an inhibitory effect. Also in
this case, analysis of consensus sequences failed to show
putative transcriptional factors docking this site.
Haplotype association with nephrotic syndrome
Overall, 237 patients with primary nephrotic syndrome were
analyzed. As specified in Materials and Methods section, both
children and adults were included. Patients under 16 years
were included if presenting sensitivity to steroids and in this
case a renal biopsy was not required; other patients under-
went a renal biopsy to exclude other conditions. Over 16
years, available histology was required for enrolment. As
indicated in Table 1, age was the same in groups with
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Figure 4 | (a) EMSA experiments using podocyte nuclear extracts
and oligonucleotide 51G demonstrating the formation of a
slowly migrating complex that was not formed in case of the less
frequent variant 51T (tracks 1 and 2). Competition studies with
unlabelled 51G at three different concentrations of 100–200–400
fold molar excess and lack of competition of 51T, confirmed
specificity of the complex (tracks 5, 6, 7, and 8). Preincubation with
anti-USF1 (but not anti-cfos) antibodies abolished the formation of
the retarded complex (tracks 3 and 4) indicating that this is indeed
the transcriptional factor that binds this cis element. (b) EMSA with
canonical sequences for USF E-box, showing comigration at the same
molecular weight of the degenerate form (tracks 1 and 3). It is evident
the formation of a marked protein–DNA adduct (track 3) that
overwhelms by several factors the DNA–protein complex formed by
degenerate sequences (compare tracks 1 and 3). The presence of
anti-USF1 antibodies abolished the formation of the complex (track 4)
and produced a super-shift that is represented by a minor band with
higher molecular weight and an intensity that is less than 10% of the
original adduct, track 5 shows cells silenced for USF1.
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Figure 5 | Characterization of USF1 as the transcriptional factor
binding –51G. USF1 RNA silencing produced (a) a 50% expression
of USF1 at Western blot and (b) induced in parallel 30% reduction of
luciferase expression.
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different histology and clinical response to drugs indicating
that age is not a variable influencing these parameters. All
patients with primary nephrotic syndrome were first checked
for NPHS2 coding region mutations and those resulting
positive were excluded from the study. Also three patients
with mutations in the promoter were excluded. Details on
haplotypes frequencies in patients with nephrotic syndrome
are reported in Table 3. Haplotypes combinations of 116/
51 (C/G, C/T, T/G) did not present any variation in
nephrotic patients and were not associated with any of the
relevant clinical features, including age at onset, drugs
sensitivity, histology, and progression to ESRF. The haplotype
including the variants 535CTTTTTT3, P20L, and G34G was
found only in patients with renal disease, mostly in nephrotic
patients and less frequently in patients with IgA. Haplotype
comparisons using the PHASE 2.1 program23 showed that
cases are more similar to other cases than to controls,
rejecting the null hypothesis at a P-value of 0.038 (10 000
permutations). Similarly, permutation test using Haploview
3.222 and UNPHASED24 programs demonstrated a statisti-
cally significant association (Po0.035). This difference is due
to the absence of P20L in our control population (Table 2).
This finding suggests that P20L occurs on an ancestral
haplotypes and produces a phenotype characterized by
proteinuria when present, even as heterozygous trait.
Haplotype association with IgA
Haplotype combination frequencies and association with
clinical features of IgA patients are summarized in Tables 3–5.
The most relevant finding is pertinent to a discordance of
frequencies of 116/51 haplotypes combination. Patients
and controls showed a statistically significant difference in
haplotypes similarity (P-value 0.003, 10 000 permutations)
according to which C/G is more frequent in IgA patients
(corrected P-value¼ 0.005, Table 3) and is also associated
with main clinical features such as lower proteinuria and
serum creatinine level (CL) during the follow-up (Tables 4
and 5). In the former case, the association was evaluated in
197 patients with proteinuria 40.2 g/24 h at onset who had a
follow-up of at least 2 years; in those who were followed for
more than 5 years (136 patients) the presence of 116C/
51G haplotypes represented the unique factor inversely
correlated to high proteinuria at both univariate analysis
odds ratio (OR: 0.28, CL: 0.08–0.99, P¼ 0.026) and multi-
variate analysis (OR: 0.24, CL: 0.07–0.89, P¼ 0.015). A
parallel association, but in a shorter follow-up, was observed
between 116C/51G and CL that were less than 1.2 mg% in
those who were followed for o5 years (OR: 0.34, CL:
0.13–0.89, P¼ 0.029) suggesting that proteinuria and evolu-
tion to ESRF are linked to the NPHS2 promoter background
in the frame of a multifactorial pathogenesis.
1 2 3 4 5
100× 200×
cold probe
400×
WT–116T
Figure 6 | EMSA experiments using podocyte nuclear extracts and
oligonucleotide 116C, demonstrating the formation of a slowly
migrating complex (arrow) that was not formed in case of
the less frequent variant 116T (tracks 1 and 2). Competition
studies with unlabelled 116C at three different concentrations of
100–200–400 fold molar excess and lack of competition of 116T
confirmed specificity of the complex (tracks 3, 4 and 5).
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Figure 7 | EMSA experiments using podocyte nuclear extracts and
oligonucleotide 535CTTTTTT3 demonstrating the formation of
a slowly migrating complex (track 2) that was not formed in case
of the less frequent variant 535CTTTTTT2 (track 1).
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DISCUSSION
Podocin has a central role in maintaining the slit-diaphragm
homeostasis, connecting the main slit protein nephrin to the
cell body, allowing flexibility to the whole complex.
According to this concept, podocin knockout is linked to
proteinuria and renal failure in mice10 and the same occurs in
patients with homozygous/compound-heterozygous muta-
tions of the NPHS2 gene.11–13 Functional integrity of the slit
diaphragm not only requires normal podocin but also
sufficient amount of protein. During proteinuria, podocin
and nephrin are lost from the podocyte14–16,25,26 body and
should be restored by re-synthesis. We recently demonstrated
that the region spanning from –628 base pairs to the ATG of
the NPHS2 gene is able to specifically direct podocin
expression in several cell lines.20 Here we show the presence
of three new variants, with a minor allele frequency 41%,
suitable for case–control association studies. This region is
organized, together with variants in the NPHS2 gene, in
haplotype blocks, one of which (116/51) is in strict
linkage disequilibrium in cases and controls. A second
haplotype (535CTTTTTT3/P20L/G34G) appears to be
represented only in patients, mainly the subgroup affected
by nephrotic syndrome. All the above sequences were first
evaluated on functional basis utilizing specific expression
assays and gel-retardations experiments and were found
critical in driving cell expression of the reporter gene. Any
variant at each site determines a drastic downregulation of
reporter expression up to 80% indicating the possibility of
high- and low-profile NPHS2 promoter haplotypes.
A significant part of our work was devoted to the
characterization of putative trans-acting elements, to their
specificity for the binding sites and specific regulatory
proteins. We furnished conclusive information on the
binding at 51G of USF1, that was identified on the basis
of inhibition of the DNA–protein adduct by specific
antibodies and of reduction of expression in podocytes with
reduced USF1 expression by the RNA interference. Therefore,
USF1 has to be considered as a main regulatory factor of
podocin expression in human glomeruli. Analysis of USF1
regulation should be extended to renal diseases characterized
Table 4 | Association between presence of 116C/51G haplotype in NPHS2 promoter and a high blood creatinine level at the
end of the follow-up period of 5 years in patients with IgA nephrites
Univariate analysis Multivariate analysisa
116C/51G Number of patients OR 95% CI P OR 95% CI P
Whole period 0.116 0.142
No 69 1 (ref.) — 1 (ref.) —
Yes 184 0.64 0.37; 1.1 0.63 0.34; 1.2
p5 years 0.029 0.052
No 29 1 (ref.) — 1 (ref.) —
Yes 51 0.34 0.13; 0.89 0.36 0.12; 1.0
45 years 0.814 0.654
No 40 1 (ref.) — 1 (ref.) —
Yes 133 0.92 0.45; 1.9 0.83 0.38; 1.9
CI, confidence interval; OR, odds ratio; ref., reference.
Bold indicates statistical different OD, italic shows the 95% Cl range.
aAdjusted for age at the onset and gender.
Table 5 | Association between presence of haplotype 116C/51G in NPHS2 promoter and a high proteinuria level measured
at the end of the follow-up period, in patients with IgA nephropathy and proteinuria at the onset 40.2 g
Univariate analysis Multivariate analysisa
116C/51G Number of patients OR 95% CI P OR 95% CI P
Whole period 0.024 0.015
No 54 1 (ref.) — 1 (ref.) —
Yes 143 0.37 0.15; 0.94 0.34 0.13; 0.87
p5 years 0.578 0.441
No 23 1 (ref.) — 1 (ref.) —
Yes 38 0.66 0.15; 2.9 0.54 0.11; 2.7
45 years 0.026 0.015
No 31 1 (ref.) — 1 (ref.) —
Yes 105 0.28 0.08; 0.99 0.24 0.07; 0.89
CI, confidence interval; OR, odds ratio; ref., reference.
Bold indicates statistical different OD, italic shows the 95% Cl range.
aAdjusted for age at the onset and gender.
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by glomerular damage and proteinuria. As for the other two
cis elements located at 535 and 116, the molecular
approach led to the demonstration of clear DNA–protein
binding, but the identity of the trans factors remained
unknown. For the 535 it was found a clear binding with the
rare allele characterized by insCTTTTTT that was abolished
in the case of the more frequent allele with 535CTTTTTT2.
As the former allele is also associated with low promoter
activity, we could conclude for a protein with inhibitory
activity on podocin expression. An opposite conclusion was
reached for 116, that forms a clear DNA–protein adduct in
presence of a C that is abolished by the presence of a T at this
site that characterizes the low producer variant. In both cases,
lack of specific consensus sequences for any described
transcriptional factors blocked any evolution on character-
ization of trans-acting elements and experiments using
antibodies for the most common transcription factors were,
consequently, unsuccessful. Association studies between
clinical characteristics and outcomes, and haplotypes linked
with different podocin expression profiles were carried out in
one cohort of patients with IgA and one with nephrotic
syndrome. In the former case, a clear association was
observed between the 116C/51G haplotype and reduction
of proteinuria over years, that results in an improved
preservation of renal function. The alleles we analyzed are
likely to be old and the effect of the haplotype is neutral in
the absence of renal disease. This is expected according to the
fact that these are common variants that act as genetic
modifiers on a multifactorial background. The observation of
a higher frequency of the haplotype 116C/51G in patients
with IgA fits in an evolutional theory of natural selection: we
can in fact hypothesize that this haplotype was subjected to a
positive selective pressure as protective in a population with
high prevalence of glomerular diseases. This point seems
particularly interesting as prospects a new interpretative key
of the mechanism leading to progression of IgA that have
been historically linked to proteinuria.27–30 Preservation of an
intact slit diaphragm structure appears determinant in this
setting and we support the basic application of NPHS2
promoter haplotypes study in trials on long-term outcome in
IgA patients that utilize drugs that may modify the slit-
diaphragm composition such as angiotensin-converting
enzyme inhibithors.
As for FSGS, we could show the association of P20L with
535CTTTTTT3 that was uniquely observed in such patients
and in two cases with IgA. P20L is a mutation affecting exon
1 of NPHS2, not associated with functional anomalies, that
has been found almost exclusively in patients with FSGS. For
this reason, it was considered as a rare variant of unknown
significance. The uniqueness of the association of P20L with
the low producer 535CTTTTTT3 variant in a single
haplotype suggests strict implication in proteinuria, even if
the functional effect of a heterozygous alteration in a
recessive trait appears unusual and can only be explained
on the basis of haplo-insufficiency. The concomitance of mild
functional defect conferred by the amino-acid change (P20L)
and the very low-expression profile conferred by the
promoter variant (535CTTTTTT3) appears necessary for
the phenotype in these patients. Apart this main finding, we
could not demonstrate any association of NPHS2 promoter
haplotypes with different forms of primary nephrotic
syndrome. In particular, no difference related to the age
and/or between FSGS vs other histology variants were found
that were expected on the basis of data on podocin
expression differences. Probably, other works should focus
on glomerular podocin expression in different clinical and
pathologic variants before any conclusion on a key aspect of
primary nephrotic syndrome.
In conclusion, our study describes three functional
polymorphisms in NPHS2 promoter, two of which appear
to be important in determining proteinuria and long-term
outcome in patients with glomerular diseases. In one case,
USF1 was characterized as the trans element that binds
specifically 51G and markedly modify the podocin profile.
Future studies should consider NPHS2 functional haplotypes
and trans element glomerular expression in different renal
pathologies.
MATERIALS AND METHODS
Patient cohorts
We screened 545 patients with glomerular disease (nephrotic
syndrome and IgA) and 204 healthy blood donors controls. For all
we had an informed consent for molecular studies on their DNA.
For individuals below age 18 years the consent was given by one
parent.
Nephrotic syndrome. The patients cohort was represented by
237 cases (Table 1). Consolidated therapeutic schemes were
adopted.31,32 Renal histology was available in 217 cases: 138 had a
diagnosis of FSGS based on the histological evidence of at least one
segmental area of glomerulosclerosis, 54 presented mesangial IgM
deposition, and 25 minimal change nephropathy.33 Most presented
strict resistance to steroids and were then treated with drug
associations, including cyclosporine. Evolution to ESRF was
documented in 79 patients (33.3%). These patients represent the
cohort without NPHS2 mutation of an originally group of 267
patients with nephrotic syndrome who had been checked for
mutation of NPHS2 coding region. Twenty-seven patients with
causative mutations in the coding region and three with rare
variants in the promoter were excluded from the study.
IgA nephropathy. We recruited 308 patients with biopsy-
proven IgA (Table 1).
NPHS2 DNA sequence
Molecular analysis of podocin coding region was performed by
direct sequencing as already described.12,34,35
NPHS2 promoter sequence
NPHS2 promoter from 628 to ATG was sequenced as above using
the following polymerase chain reaction primers: forward: 50-GA
AAGTTGGGGATGAGGCGA-30; reverse: 50-CAATCAAAGCTTCCT
CAGAGCTGCCGGGCGGCT-30.
NPHS2 promoter constructs-luciferase assay
NPHS2 promoter polymerase chain reaction products were
subcloned into the luciferase pGL3 reporter vector (Promega Inc.,
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Madison, WI, USA). All clones, bearing a specific mutation
(pPL1–pPL4) and the wild-type clone (pPL5), were sequenced prior
transfection. Luciferase activity was determined in a TD-20/20
luminometer (Turner Designs, Sunnyvale, CA, USA) according to
the Promega luciferase assay (Promega Inc., Madison, WI, USA) and
results were normalized to the cotransfected Renilla luminescence.
Results are given as arbitrary units.36
Cell culture
COS7 (monkey renal fibroblasts) were obtained from American
Type Culture Collection (Rockville, MD, USA) and were grown
under humidified atmosphere of 5% CO2 at 971C in Dulbecco’s
modified Eagle’s medium supplemented with 10% calf serum, 1%
L-glutamine, 100mg/ml streptomycin, 100 U/ml penicillin. An
immortalized glomerular epithelial cell line was cultured in
Dulbecco’s modified Eagle’s medium containing 25 mM glucose,
10% inactivated fetal calf serum, 100 U/ml penicillin, and 100 mg/ml
streptomycin at 371C.25
Transfection experiments
Transfection experiments were performed with standard podocytes,
podocytes silenced for USF1 and COS7, using 4 mg plasmids
following the polyethilenimine (25 kDa polyethyleneimine, Sigma,
St Louis, MO, USA) procedure. Thirty microliters of a 10 mM
polyethyleneimine solution were added to 10 mg DNA and incubated
at 371C for 3 h in 5% CO2. Cells were incubated for 48 h before
being processed with the luciferase assay.
Nuclear extracts and cellular fractionation
Podocytes were scraped with a rubber policeman, pelleted at 600 g
for 10 min and resuspended in 200 ml/100 mm plate of 20 mM N-[2-
hydroxyethyl]piperazine-N0-[2-ethanesulfonic acid] (pH 7.9), 1 mM
ethylenediaminetetraacetic acid, 1 mM dithiotreitol, 0.5 mM phenyl-
methylsulfonyl flouride, 1 mg/ml of leupeptin, pepstatin, and
aprotinin, 1 mM sodium vanadate, 10 mM sodium fluoride, and
kept at 41C for 15 min. Cell suspension was added with 1/4 volume
of 1% NP40 to obtain a final concentration of 0.2% NP40,
incubated at 41C for 15 min and centrifuged at 600 g for 15 min. The
supernatant (S1) was saved for further processing, whereas the pellet
(P1), was resuspended in 1 volume of low salt buffer (LSB) (20 mM
N-[2-hydroxyethyl]piperazine-N0-[2-ethanesulfonic acid] (pH 7.9),
1.5 mM MgCl2, 0.2 mM ethylenediaminetetraacetic acid, 0.5 mM
dithiotreitol, 0.5 mM phenylmethylsulfonyl flouride, 80 mM NaCl,
25% glycerol). After extensive mixing, 1 volume of high salt buffer
(HSB) (as in BLS, containing 0.9 M NaCl) was added and incubated
at 41C for 30 min. P1 was centrifuged at 16 000 g for 30 min. The
supernatant fraction (S2) was collected and used as nuclear extract
for gel retardation assay.
Transient siRNA-mediated silencing of USF1
Transient transfection of small interfering RNA (siRNA) for
targeting endogenous gene silencing was performed using poly-
ethyleneimine 25 kDa and 200 nM siRNA duplex per well. The
following Qiagen siRNA oligonucleotides (Hs_USF_1_HP siRNA,
catalog number SI00094815) were used: sense: r(GAUUAGAGGUC
GUCAUCAA) dTdT; antisense: r(UUGAUGACGACCUCUAAUC)
dCdG, corresponding to base pairs between 1092 and 1112
downstream the start codon sequence GAUUAGAGGUCGUCAU
CAA. Cells were assayed for 48 h after transfection.
Statistics
Haplotype reconstruction and case–control permutation tests were
performed using Haploview 3.2,22 PHASE 2.0,23 and UNPHASED
2.40424 programs. The Haplotypes inference was carried out
through Haploview 3.2, confirmed using PHASE 2.0, analyzing
cases alone, controls alone, and the whole data set. The pair-wise
linkage disequilibrium statistic (D0) was calculated using Haploview
3.2 with the solid spine of LD algorithm.37 A triangular matrix of D0
was used to demonstrate LD patterns in cases and controls.
Case–control association study was first conducted using PHASE
program, testing the null hypothesis that cases and controls
haplotypes are random samples from a single set of haplotype
frequencies, vs the alternative hypothesis that cases are more similar
to each other than to controls. In this scenario the test gives a global
P-value that reflects the similarity of the haplotypes between cases
and controls. This test has power even when every haplotype in the
data set is unique. For this analysis, 100 iterations and 10 000
permutations were run. The results have been confirmed with an
independent analysis using the UNPHASED program, running
10 000 permutations as well. The haplotypes that gave significant
global P-values were then tested for association by w2-test and the
significance values corrected through permutation test as imple-
mented in the Haploview 3.2 software.
The association between the presence of NPHS2 promoter
haplotypes and creatinine and proteinuria levels, in patients with a
length of follow-up p5 years, was assessed in terms of OR by a
logistic regression model, adjusting for the confounder effects of
gender and age at the onset. OR values 41 indicated a positive
association, whereas values o1 indicated a protective effect of the
haplotype. Thersholds for normality were 1.2 mg/dl for CL and
0.2 g/day for proteinuria.
Statistical significance of OR (a¼ 0.05) was assessed via
likelihood ratio test and the corresponding 95% confidence intervals
obtained by the Wald method, which assumes a log-normal
distribution for the OR estimates. Logistic LP models were fitted
using STATA software, release 7.0 (STATA Corp. LP, TX, USA, 2001).
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